ACELYRIN (SLRN) Q3 2024 earnings summary

Executive summary

• Refocused pipeline prioritizes late-stage development of lonigutamab for thyroid eye disease (TED), with Phase 3 initiation expected in Q1 2025 following positive FDA feedback and proof-of-concept data.

• Advanced izokibep in uveitis, with topline Phase 2b/3 data expected December 2024; internal development in other indications discontinued.

• August 2024 restructuring plan suspended new internal investment in izokibep for HS, PsA, and AxSpA, reducing workforce by about one-third.

• Net loss for the nine months ended September 30, 2024 was $169.2 million, a significant improvement from $286.4 million in the prior year.

• Established a scientific and patient advisory board to guide lonigutamab's clinical development.

Financial highlights

• Ended Q3 2024 with $562.4 million in cash, cash equivalents, and short-term marketable securities, supporting operations to at least mid-2027.

• Q3 2024 research and development expenses were $31.6 million, down from $74.6 million year-over-year.

• General and administrative expenses were $12.3 million, down from $19.9 million year-over-year.

• Net loss for Q3 2024 was $48.5 million, compared to $83.9 million in Q3 2023; net loss per share was $0.49 versus $0.87.

• Updated year-end 2024 cash guidance to $435 million-$450 million, including a $31 million license payment for lonigutamab.

Outlook and guidance

• Phase 3 program for lonigutamab in TED expected to start in Q1 2025, with full program design and timelines to be shared in early 2025.

• Topline results for Phase 2b/3 izokibep trial in uveitis anticipated in December 2024, with future development contingent on data.

• Cash runway projected to mid-2027, supporting all planned lonigutamab development through potential BLA filing.